Similar articles

Abstract: Infection with hepatitis C virus (HCV) affects approximately 170 million people worldwide. However, no vaccine or immunoglobulin is currently available for the prevention of HCV infection. The standard of care (SOC) involving pegylated interferon-α (PEG-IFN α) plus ribavirin (RBV) for 48 weeks results in a sustained virologic response in less than 50% of patients with chronic hepatitis C genotype 1, the most prevalent type of HCV in North America and Europe. Recently, reliable in vitro culture systems have been developed for accelerating antiviral therapy research, and many new specifically targeted antiviral therapies for hepatitis C (STAT-C) and treatment strategies are being evaluated in clinical trials. These new antiviral agents are expected to improve present treatment significantly and may potentially shorten treatment duration. The aim of this review is to summarize the current developments in new anti-HCV drugs.

[1]Ali, S., Leveque, V., Le Pogam, S., Ma, H., Philipp, F., Inocencio, N., Smith, M., Alker, A., Kang, H., Najera, I., et al., 2008. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob. Agents Chemother., 52(12):4356-4369.

[2]Bavisotto, L., Wang, C.C., Jacobson, I.M., Marcellin, P., Zeuzem, S., Lawitz, E.J., Lunde, M., Sereni, P., O′Brien, C., Oldach, D.W., et al., 2007. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects. Hepatology, 46(4):255A.

[3]Bedard, J., Nicolas, O., Bilimoria, D., L′Heureux, L., Fex, P., David, M., Chan, L., 2009. Identification and characterization of VCH-222, a novel potent and selective non-nucleoside HCV polymerase inhibitor. J. Hepatol., 50(S1):S340.

[4]Boerner, J., Ma, S., Compton, T., Lin, K., 2007. NIM811, a cyclophilin inhibitor, and NM107, an HCV polymerase inhibitor, synergistically inhibits HCV replication and suppresses the emergence of resistance in vitro. Antivir. Res., 74(3):A57.

[5]Brown, N.A., 2009. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues. Expert Opin. Inv. Drugs, 18(6):709-725.

[6]Burton, J.R., Everson, G.T., 2009. HCV NS5B polymerase inhibitors. Clin. Liver Dis., 13(3):453-465.

[7]Cai, Z., Zhang, C., Chang, K.S., Jiang, J., Ahn, B.C., Wakita, T., Liang, T.J., Luo, G., 2005. Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J. Virol., 79(22):13963-13973.

[8]Carroll, S.S., Ludmerer, S., Handt, L., Koeplinger, K., Zhang, N.R., Graham, D., Davies, M.E., MacCoss, M., Hazuda, D., Olsen, D.B., 2009. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob. Agents Chemother., 53(3):926-934.

[9]Chatterji, U., Lim, P., Bobardt, M.D., Wieland, S., Cordek, D.G., Vuagniaux, G., Chisari, F., Cameron, C.E., Targett-Adams, P., Parkinson, T., et al., 2010. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol., 53(1):50-56.

[10]Chauret, N., Chagnon-Labelle, C., Diallo, M., Laquerre, J., Laterreur, J., May, S., Ste-Marie, L., 2009. Preclinical pharmacokinetic and ADME characterization of VCH-222, a novel non-nucleoside HCV NS5B polymerase inhibitor. J. Hepatol., 50(S1):S341-S342.

[11]Chen, K.X., Njoroge, F.G., 2009. A review of HCV protease inhibitors. Curr. Opin. Investig. Drugs, 10(8):821-837.

[12]Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M., 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244(4902):359-362.

[13]Coelmont, L., Gallay, P., Bobardt, M., Kaptein, S., Paeshuyse, J., Vliegen, I., Vuagniaux, G., Neyts, J., 2009a. In vitro anti-hepatitis C virus (HCV) activities and resistance profile of Debio 025, a non-immunosuppressive cyclophilin binding molecule. Antivir. Res., 82(2):A20.

[14]Coelmont, L., Gallay, P., Bobardt, M., Kaptein, S., Paeshuyse, J., Vliegen, I., Vuagniaux, G., Neyts, J., 2009b. Particular in vitro anti-HCV activities and resistance profile of the cyclophilin inhibitor Debio 025. J. Hepatol., 50(S1):S36.

[15]Coelmont, L., Hanoulle, X., Chatterji, U., Berger, C., Snoeck, J., Bobardt, M., Lim, P., Vliegen, I., Paeshuyse, J., Vuagniaux, G., et al., 2010. DEB025 (alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS ONE, 5(10):e13687.

[16]Cooper, C., Lawitz, E.J., Ghali, P., Rodriguez-Torres, M., Anderson, F.H., Lee, S.S., Proulx, L., 2007. Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic hepatitis C patients: Results from a randomized, double-blind, placebo-controlled, ascending multiple dose study. Hepatology, 46(4):864A.

[17]Cooper, C., Larouche, R., Bourgault, B., Chauret, N., Proulx, L., 2009a. Safety, tolerability and pharmacokinetics of the HCV polymerase inhibitor VCH-222 following single dose administration in healthy volunteers and antiviral activity in HCV-infected individuals. J. Hepatol., 50(S1):S342.

[18]Cooper, C., Lawitz, E.J., Ghali, P., Rodriguez-Torres, M., Anderson, F.H., Lee, S.S., Bedard, J., Chauret, N., Thibert, R., Boivin, I., et al., 2009b. Evaluation of VCH-759 monotherapy in hepatitis C infection. J. Hepatol., 51(1):39-46.

[19]Cretton-Scott, E., Perigaud, C., Peyrottes, S., Licklider, L., Camire, M., Larsson, M., La Colla, M., Hildebrand, E., Lallos, L., Bilello, J., et al., 2008. In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication. J. Hepatol., 48(S2):S220.

[20]de Bruijne, J., Weegink, C.J., Jansen, P.L.M., Reesink, H.W., 2009. New developments in the antiviral treatment of hepatitis C. Vox Sanguinis, 97(1):1-12.

[21]Delang, L., Coelmont, L., Neyts, J., 2010. Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses, 2(4):826-866.

[22]Deutsch, M., Papatheodoridis, G.V., 2010. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection. Curr. Opin. Investig. Drugs, 11(8):951-963.

[23]Feld, J.J., Hoofnagle, J.H., 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, 436(7053):967-972.

[24]Fischer, G., Gallay, P., Hopkins, S., 2010. Cyclophilin inhibitors for the treatment of HCV infection. Curr. Opin. Investig. Drugs, 11(8):911-918.

[25]Flisiak, R., Feinman, S.V., Jablkowski, M., Horban, A., Kryczka, W., Halota, W., Heathcote, J.E., Mazzella, G., Vandelli, C., Liz, J.S., et al., 2008a. Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon α-2a in treatment naive chronic HCV patients. J. Hepatol., 48(S2):62.

[26]Flisiak, R., Horban, A., Gallay, P., Bobardt, M., Selvarajah, S., Wiercinska-Drapalo, A., Siwak, E., Cielniak, I., Higersberger, J., Kierkus, J., et al., 2008b. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology, 47(3):817-826.

[27]Flisiak, R., Woynarowski, M., Jablkowski, M., Halota, W., Kryczka, W., Horban, A., Czauz-Andrzejuk, A., Bialkowska, J., Pawlowska, M., Zarebska-Michaluk, D., et al., 2010. Efficacy of standard of care therapy following experimental Debio 025 treatment in patients with chronic hepatitis C. J. Hepatol., 52(S1):S291.

[28]Foy, E., Li, K., Sumpter, R.Jr., Loo, Y.M., Johnson, C.L., Wang, C., Fish, P.M., Yoneyama, M., Fujita, T., Lemon, S.M., et al., 2005. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. PNAS, 102(8):2986-2991.

[29]Franco, S., Parera, M., Aparicio, E., Clotet, B., Martinez, M.A., 2007. Genetic and catalytic efficiency structure of an HCV protease quasispecies. Hepatology, 45(4):899-910.

[30]Franco, S., Clotet, B., Martinez, M.A., 2008. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals. Virus Res., 131(2):260-270.

[31]Fridell, R.A., Qiu, D.K., Wang, C.F., Valera, L., Gao, M., 2010. Resistance analysis of the HCV NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother., 54(9):3641-3650.

[32]Friebe, P., Lohmann, V., Krieger, N., Bartenschlager, R., 2001. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. J. Virol., 75(24):12047-12057.

[33]Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L.Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al., 2002. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 347(13):975-982.

[34]Gaither, L.A., Borawski, J., Anderson, L.J., Balabanis, K.A., Devay, P., Joberty, G., Rau, C., Schirle, M., Bouwmeester, T., Mickanin, C., et al., 2010. Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology, 397(1):43-55.

[35]Galat, A., 2004. Function-dependent clustering of orthologues and paralogues of cyclophilins. Prot. Struct. Funct. Bioinf., 56(4):808-820.

[36]Gane, E., Foster, G.R., Cianciara, J., Stedman, C., Ryder, S., Buti, M., Clark, E., Tait, D., 2010a. Antiviral activity, pharmacokinetics, and tolerability of AZD7295, a novel NS5A inhibitor, in a placebo-controlled multiple ascending dose study in HCV genotype 1 and 3 patients. J. Hepatol., 52(S1):S464.

[37]Gane, E., Roberts, S., Stedman, C., Angus, P., Ritchie, B., Elston, R., Ipe, D., Morcos, P., Baher, L., Najera, I., et al., 2010b. Early on-treatment responses during pegylated IFN plus ribavirin are increased following 13 days of combination nucleoside polymerase (RG7128) and protease (RG7227) inhibitor therapy (INFORM-1). J. Hepatol., 52(S1):S291-S292.

[38]Gane, E.J., Roberts, S.K., Stedman, C.A., Angus, P.W., Ritchie, B., Elston, R., Ipe, D., Morcos, P.N., Baher, L., Najera, I., et al., 2010c. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet, 376(9751):1467-1475.

[39]Gane, E., Rouzier, R., Stedman, C., Wiercinska-Drapalo, A., Horban, A., Chang, L., Zhang, Y., Sampeur, P., Najera, I., Shulman, N., et al., 2010d. Ritonavir boosting of low dose RG7227/ITMN-191, HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens. J. Hepatol., 52(S1):S16-S17.

[40]Gane, E.J., Rodriguez-Torres, M., Nelson, D.E., Jacobson, I.M., McHutchison, J.G., Duca, A., Hyland, R., Hill, G., Albanis, E., Symonds, W.T., et al., 2010e. Sustained virologic response (SVR) following RG7128 1500 mg BID PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders. J. Hepatol., 52(S1):S16.

[41]Gao, M., Nettles, R.E., Belema, M., Snyder, L.B., Nguyen, V.N., Fridell, R.A., Serrano-Wu, M.H., Langley, D.R., Sun, J.H., O′Boyle, D.R., et al., 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature, 465(7294):96-100.

[42]Goto, K., Watashi, K., Murata, T., Hishiki, T., Hijikata, M., Shimotohno, K., 2006. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem. Biophys. Res. Commun., 343(3):879-884.

[43]Grakoui, A., McCourt, D.W., Wychowski, C., Feinstone, S.M., Rice, C.M., 1993. A second hepatitis C virus-encoded proteinase. PNAS, 90(22):10583-10587.

[44]Hadziyannis, S.J., Sette, H.Jr., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H.Jr., Bernstein, D., Rizzetto, M., et al., 2004. Peginterferon-α 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med., 140(5):346-355.

[45]Hayashi, N., Takehara, T., 2006. Antiviral therapy for chronic hepatitis C: past, present, and future. J. Gastroenterol., 41(1):17-27.

[46]Herrmann, E., Kafer, A., Flisiak, R., Nicolas-Metral, V., Zeuzem, S., Crabbe, R., 2009. PK-PD modeling of viral kinetics during treatment with Debio-025 plus pegylated interferon α-2a in treatment-naive HCV patients. J. Hepatol., 50(S1):S344.

[47]Hezode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.P., Bourliere, M., Gharakhanian, S., Bengtsson, L., et al., 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med., 360(18):1839-1850.

[48]Hopkins, S., Huang, Z.H., Scribner, A., Peel, M., 2009a. Antiviral activity of the non-immunosuppressive cyclophilin inhibitor SCY-635 in combination with investigational and approved anti-HCV agents. Hepatology, 50(4):1042A.

[49]Hopkins, S., Heuman, D., Gavis, E., Lalezari, J., Glutzer, E., DiMassimo, B., Rusnak, P., Wring, S., Smitley, C., Ribeill, Y., 2009b. Safety, plasma pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection. J. Hepatol., 50(S1):S36.

[50]Hopkins, S., Scorneaux, B., Huang, Z.H., Murray, M.G., Wring, S., Smitley, C., Harris, R., Erdmann, F., Fischer, G., Ribeill, Y., 2010. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob. Agents Chemother., 54(2):660-672.

[51]Horban, A., Berak, H., Kolakowska-Rzadzka, A., Patel, H., Flisiak, R., Crabbe, R., Liz, J.S., Heathcote, J.E., 2010. Sustained virological response after 4-week treatment with Debio 025 monotherapy or coadministered with PEG-IFN α-2a in HCV genotype 1 and 3 patients. J. Hepatol., 52(S1):S294.

[52]Houck, D.R., Hopkins, S., 2006. Preclinical evaluation of SCY-635, a cyclophilin inhibitor with potent anti-HCV activity. Hepatology, 44(S1):534A-535A.

[53]Houghton, M., Abrignani, S., 2005. Prospects for a vaccine against the hepatitis C virus. Nature, 436(7053):961-966.

[54]Inoue, K., Sekiyama, K., Yamada, M., Watanabe, T., Yasuda, H., Yoshiba, M., 2003. Combined interferon α-2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J. Gastroenterol., 38(6):567-572.

[55]Inoue, K., Umehara, T., Ruegg, U.T., Yasui, F., Watanabe, T., Yasuda, H., Dumont, J.M., Scalfaro, P., Yoshiba, M., Kohara, M., 2007. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology, 45(4):921-928.

[56]Jacobson, I., Pockros, P., Lalezari, J., Lawitz, E., Rodriguez-Torres, M., DeJesus, E., Haas, F., Martorell, C., Pruitt, R., Durham, K., et al., 2009. Antiviral activity of Filibuvir in combination with pegylated interferon α-2a and Ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1. J. Hepatol., 50(S1):S382-S383.

[57]Jacobson, I., Pockros, P.J., Lalezari, J., Lawitz, E., Rodriguez-Torres, M., DeJesus, E., Haas, F., Martorell, C., Pruitt, R., Purohit, V., et al., 2010. Virologic response rates following 4 weeks of Filibuvir in combination with pegylated interferon alfa-2a and Ribavirin in chronically-infected HCV genotype-1 patients. J. Hepatol., 52(S1):S465.

[58]Karakama, Y., Sakamoto, N., Itsui, Y., Nakagawa, M., Tasaka-Fujita, M., Nishimura-Sakurai, Y., Kakinuma, S., Oooka, M., Azuma, S., Tsuchiya, K., et al., 2010. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. Antimicrob. Agents Chemother., 54(8):3179-3186.

[59]Ke, J., Lawitz, E., Rozier, R., Marbury, T., Nguyen, N., Serra, D., Dole, K., Praestgaard, J., Huang, M., Evans, T., 2009. Safety, and tolerability of NIM 811, a novel cyclophilin inhibitor for HCV, following single and multiple ascending doses in healthy volunteers and HCV-infected patients. J. Hepatol., 50(S1):S229.

[60]Kirkovsky, L., Zhou, Y., Norris, D., Okamoto, E., Nolan, T.G., Bartkowski, D., Khandurina, J., Sergeeva, M., Murphy, D., Ayida, B., et al., 2007. ANA598, a novel non-nucleoside inhibitor of HCV NS5B polymerase, exhibits favorable pharmacokinetic properties in multiple preclinical species. Hepatology, 46(S1):858A.

[61]Klumpp, K., Smith, D., Brandl, M., Alfredson, T., Sarma, K., Smith, M., Najera, I., Jiang, W.R., Le Pogam, S., Leveque, V., et al., 2007. Design and characterization of R1626, a prodrug of the HCV replication inhibitor R1479 (4′-azidocytidine) with enhanced oral bioavailability. Antivir. Res., 74(3):A35.

[62]Kolykhalov, A.A., Mihalik, K., Feinstone, S.M., Rice, C.M., 2000. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol., 74(4):2046-2051.

[63]Kukolj, G., Benhamou, Y., Manns, M.P., Bourliere, M., Pol, S., Schuchmann, M., Cartier, M., Huang, D., Lagace, L., Steinmann, G., et al., 2009. BI 201335, a potent HCV NS3 protease inhibitor, in treatment-naive and -experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain. J. Hepatol., 50(S1):S347.

[64]Kukolj, G., Bousquet, C., Dansereau, N., Do, F., Lagace, L., Llinas-Brunet, M., Marquis, M., Massariol, M.J., Maurice, R., Spickler, C., et al., 2010. Characterization of resistant mutants selected in vitro by the HCV NS3/4A protease inhibitor BI 201335. J. Hepatol., 52(S1):S295.

[65]Kwo, P.Y., Lawitz, E.J., McCone, J., Schiff, E.R., Vierling, J.M., Pound, D., Davis, M.N., Galati, J.S., Gordon, S.C., Ravendhran, N., et al., 2010. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon α-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet, 376(9742):705-716.

[66]Lalezari, J., Asmuth, D., Casiro, A., Vargas, H.E., Patrick, G.D., Liu, W., Pietropaolo, K., Zhou, X.J., Sullivan-Bolyai, J., Mayers, D.L., 2009. Antiviral activity, safety and pharmacokinetics of IDX184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. Hepatology, 50(6):11A-12A.

[67]Lallos, L., LaColla, M., Serra, I., Bilello, J.P., Soubasakos, M.A., Li, B., Panzo, R.J., Gillum, J.M., Bonin, A., Seifer, M., et al., 2009. Combination of IDX184, a nucleotide prodrug polymerase inhibitor, with other classes of HCV inhibitors is additive to synergistic in the HCV replicon in vitro. Hepatology, 50(4):1045A.

[68]Lam, A.M., Frick, D.N., 2006. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J. Virol., 80(1):404-411.

[69]Larrey, D., Benhamou, Y., Lohse, A.W., Trepo, C., Moelleken, C., Bronowicki, J.P., Heim, M.H., Arasteh, K., Zarski, J.P., Bourliere, M., et al., 2009a. BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C. Hepatology, 50(4):1044A.

[70]Larrey, D., Benhamou, Y., Lohse, A.W., Trepo, C., Moelleken, C., Bronowicki, J.P., Arasteh, K., Bourliere, M., Heim, M., Enriquez, J., et al., 2009b. Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J. Hepatol., 50(S1):S383-S384.

[71]Lavanchy, D., 2009. The global burden of hepatitis C. Liver Int., 29(1):74-81.

[72]Lawitz, E., Rouzier, R., Nguyen, T., Huang, M., Ke, J., Praestgaard, J., Serra, D., Koziel, M., Evans, T., 2009. Safety and antiviral efficacy of 14 days of the cycophilin inhibitor NIM811 in combination with pegylated interferon α-2a in relapsed genotype 1 HCV infected patients. J. Hepatol., 50(S1):S379.

[73]Lawitz, E.J., Marbury, T.C., Vince, B.D., Grunenberg, N., Rodriguez-Torres, M., de Micco, M.P., Tarro, J.N., Shelton, M.J., West, S., Zong, J., et al., 2010. Dose-ranging, three-day monotherapy study of the HCV NS3 protease inhibitor GS-9256. J. Hepatol., 52(S1):S466-S467.

[74]Lawitz, E., Rodriquez-Torres, M., Rustgi, V.K., Hassanein, T., Rahimy, M.H., Crowley, C.A., Freddo, J.L., Muir, A., McHutchison, J., 2010a. Safety and antiviral activity of ANA598 in combination with pegylated interferon α-2a plus ribavirin in treatment-naive genotype-1 chronic HCV patients. J. Hepatol., 52(S1):S467.

[75]Le Pogam, S., Seshaadri, A., Ewing, A., Kang, H.S., Kosaka, A., Yan, J.M., Berrey, M., Symonds, B., de la Rosa, A., Cammack, N., et al., 2010. RG7128 alone or in combination with pegylated interferon-α 2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J. Infect. Dis., 202(10):1510-1519.

[76]Lemke, C.T., Zhao, S.P., Goudreau, N., Hucke, O., Thibeault, D., Llinas-Brunet, M., White, P.W., 2010. Bound structure and biochemical mechanism of action of BI 201335, a potent, non-covalent inhibitor of HCV NS3-NS4A protease. Antivir. Res., 86(1):A20-A21.

[77]Levin, J., Eley, T., Pasquinelli, C., Wendelburg, P., Villegas, C., He, B., Liao, S., Jiang, H., Marbury, T., Bertz, R., et al., 2010. Safety and Pharmacokinetics of BMS-650032 Following Multiple Ascending Doses for 14 Days in Healthy Subjects. Bristol-Myers Squibb, Princeton, FL.

[78]Li, H., Tatlock, J., Linton, A., Gonzalez, J., Jewell, T., Patel, L., Ludlum, S., Drowns, M., Rahavendran, S.V., Skor, H., et al., 2009. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo [1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J. Med. Chem., 52(5):1255-1258.

[79]Lin, C., Kwong, A.D., Perni, R.B., 2006. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets, 6(1):3-16.

[80]Lin, K., Kwong, A.D., Lin, C., 2004. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and α interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob. Agents Chemother., 48(12):4784-4792.

[81]Lin, K., Perni, R.B., Kwong, A.D., Lin, C., 2006. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob. Agents Chemother., 50(5):1813-1822.

[82]Lin, T.L., Lenz, O., Fanning, G., Verbinnen, T., Delouvroy, F., Scholliers, A., Vermeiren, K., Rosenquist, A., Edlund, M., Samuelsson, B., et al., 2009. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob. Agents Chemother., 53(4):1377-1385.

[83]Lindenbach, B.D., Evans, M.J., Syder, A.J., Wolk, B., Tellinghuisen, T.L., Liu, C.C., Maruyamam, T., Hynes, R.O., Burton, D.R., McKeating, J.A., et al., 2005. Complete replication of hepatitis C virus in cell culture. Science, 309(5734):623-626.

[84]Liu-Young, G., Kozal, M.J., 2008. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care St., 22(6):449-457.

[85]Liverton, N.J., Carroll, S.S., Dimuzio, J., Fandozzi, C., Graham, D.J., Hazuda, D., Holloway, M.K., Ludmerer, S.W., McCauley, J.A., McIntyre, C.J., et al., 2010. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob. Agents Chemother., 54(1):305-311.

[86]Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., Bartenschlager, R., 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, 285(5424):110-113.

[87]Lok, A.S., Gardiner, D.F., Lawitz, E., Martorell, C., Everson, G.T., Ghalib, R.H., Reindollar, R., Rustgi, V.K., Wendelburg, P., Zhu, K., et al., 2010. Combination therapy with BMS-790052 and BMS-650032 alone or with pegylated interferon and ribavirin (PEGIFN/RBV) results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders. Hepatology, 52(4):877A.

[88]Ma, S., Boerner, J.E., TiongYip, C., Weidmann, B., Ryder, N.S., Cooreman, M.P., Lin, K., 2006. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with α interferon. Antimicrob. Agents Chemother., 50(9):2976-2982.

[89]Malcolm, B.A., Liu, R., Lahser, F., Agrawal, S., Belanger, B., Butkiewicz, N., Chase, R., Gheyas, F., Hart, A., Hesk, D., et al., 2006. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of α interferon in replicon cells. Antimicrob. Agents Chemother., 50(3):1013-1020.

[90]Manns, M., Reesink, H., Moreno, C., Berg, T., Benhamou, Y., Horsmans, Y., Dusheiko, G., Flisiak, R., Meyvisch, P., Lenz, O., et al., 2009. Opera-1 Trial: interim analysis of safety and antiviral activity of TMC435 in treatment-naive genotype 1 HCV patients. J. Hepatol., 50(S1):S7.

[91]Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., Albrecht, J.K., 2001. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358(9286):958-965.

[92]Manns, M.P., Foster, G.R., Rockstroh, J.K., Zeuzem, S., Zoulim, F., Houghton, M., 2007. The way forward in HCV treatment—finding the right path. Nat. Rev. Drug Discov., 6(12):991-1000.

[93]McCauley, J.A., McIntyre, C.J., Rudd, M.T., Nguyen, K.T., Romano, J.J., Butcher, J.W., Gilbert, K.F., Bush, K.J., Holloway, M.K., Swestock, J., et al., 2010. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4A protease inhibitor. J. Med. Chem., 53(6):2443-2463.

[94]McCown, M.F., Rajyaguru, S., le Pogam, S., Ali, S., Jiang, W.R., Kang, H., Symons, J., Cammack, N., Najera, I., 2008. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother., 52(5):1604-1612.

[95]McPhee, F., 2010. Identification and preclinical profile of the novel HCV NS3 protease inhibitor BMS-650032. J. Hepatol., 52(S1):S296.

[96]McPhee, F., Hernandez, D., Sheaffer, A., Lee, M., Falk, P., Yu, F., Zhai, G.Z., Chaniewski, S., Pasquinelli, C., 2009. Genotypic and phenotypic analysis of samples from HCV-infected subjects treated with BMS-650032 in a single ascending dose study. Hepatology, 50(S4):1048A.

[97]Mori, J., Hammond, J.L., Srinivasan, S., Jagannatha, S., van der Ryst, E., 2010. Genotypic characterisation of filibuvir (PF-00868554) resistance in patients receiving four weeks co-administration of filibuvir with PEGIFN/RBV (12 week analysis). J. Hepatol., 52(S1):S15.

[98]Moucari, R., Forestier, N., Larrey, D., Guyader, D., Couzigou, P., Benhamou, Y., Voitot, H., Vidaud, M., Seiwert, S., Bradford, B., et al., 2010. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut, 59(12):1694-1698.

[99]Neelakantan, S., Purohit, V.S., O′Gorman, M., Hammond, J., Tensfeldt, T.G., 2010. Exposure-response relationship of Filibuvir in HCV infected patients: application to dose selection for combination therapy. J. Hepatol., 52(S1):S119-S120.

[100]Nguyen, M.H., Keeffe, E.B., 2005. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin. Gastroenterol. Hepatol., 3(10):S97-S101.

[101]Nicolas, O., Boivin, I., St-Denis, C., Bedard, J., 2008. Genotypic analysis of HCV NS5B variants selected from patients treated with VCH-759. J. Hepatol., 48(S2):S317.

[102]Ohno, T., Mizokami, M., Tibbs, C.J., Ohba, K., Suzuki, K., Wu, R.R., Nouri-Aria, K.T., Williams, R., 1994. New genotype of hepatitis C virus in South Africa. J. Med. Virol., 42(4):409-413.

[103]Opar, A., 2010. Excitement grows for potential revolution in hepatitis C virus treatment. Nat. Rev. Drug Discov., 9(7):501-503.

[104]Otto, M.J., Robson, R., Rodríguez, C.A., Beard, A., Symonds, W.T., Hill, G., Berrey, M.M., 2007. Pharmacokinetics, Safety, and Tolerability of R7128, a Novel Nucleoside Polymerase Inhibitor for HCV Following Single, Ascending Oral Doses in Healthy Volunteers. Pharmasset Inc., Princeton, NJ.

[105]Paeshuyse, J., Kaul, A., de Clercq, E., Rosenwirth, B., Dumont, J.M., Scalfaro, P., Bartenschlager, R., Neyts, J., 2006. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology, 43(4):761-770.

[106]Patel, R., Thompson, P., Showalter, R., Appleman, J., 2010. In vitro combination studies of ANA598 with anti-HCV agents demonstrate enhanced anti-viral activity. Antivir. Res., 86(1):A41-A42.

[107]Pawlotsky, J.M., 2006. Therapy of hepatitis C: from empiricism to eradication. Hepatology, 43(S1):S207-S220.

[108]Perni, R.B., Almquist, S.J., Byrn, R.A., Chandorkar, G., Chaturvedi, P.R., Courtney, L.F., Decker, C.J., Dinehart, K., Gates, C.A., Harbeson, S.L., et al., 2006. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother., 50(3):899-909.

[109]Pockros, P., Nelson, D., Godofsky, E., Rodriguez-Torres, M., Everson, G.T., Fried, M.W., Ghalib, R., Harrison, S., Nyberg, L., Shiffman, M.L., et al., 2008a. High relapse rate seen at week 72 for patients treated with R1626 combination therapy. Hepatology, 48(4):1349-1350.

[110]Pockros, P.J., Nelson, D., Godofsky, E., Rodriguez-Torres, M., Everson, G.T., Fried, M.W., Ghalib, R., Harrison, S., Nyberg, L., Shiffman, M.L., et al., 2008b. R1626 plus peginterferon α-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology, 48(2):385-397.

[111]Pol, S., Everson, G., Ghalib, R., Rustgi, V., Martorell, C., Tatum, H.A., Lim, J., Hezode, C., Diva, U., Yin, P.D., et al., 2010. Once-daily NS5A inhibitor (BMS-790052) plus peginterferon α-2a and Ribavirin produces high rates of extended rapid virologic response in treatment-naive HCV-genotype 1 subjects: phase 2a trial. J. Hepatol., 52(S1):S462.

[112]Rahimy, M.H., Crowley, C.A., Freddo, J.L., Sergeeva, M.V., Golec, B., 2008. Results of a phase I safety, tolerability and pharmacokinetic study of ANA598, a non-nucleoside NS5B polymerase inhibitor, in healthy volunteers. Hepatology, 48(4):1026A.

[113]Reddy, R., Rodriguez-Torres, M., Gane, E., Robson, R., Lalezari, J., Everson, G.T., Dejesus, E., McHutchison, J.G., Vargas, H.E., Beard, A., et al., 2007. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology, 46(4):862A-863A.

[114]Reesink, H.W., Fanning, G.C., Farha, K.A., Weegink, C., van Vliet, A., van′t Klooster, G., Lenz, O., Aharchi, F., Marien, K., van Remoortere, P., et al., 2010. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology, 138(3):913-921.

[115]Reiser, M., Timm, J., 2009. Serine protease inhibitors as anti-hepatitis C virus agents. Expert Rev. Anti.-Infect. Ther., 7(5):537-547.

[116]Reiser, M., Hinrichsen, H., Benhamou, Y., Reesink, H.W., Wedemeyer, H., Avendano, C., Riba, N., Yong, C.L., Nehmiz, G., Steinmann, G.G., 2005. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology, 41(4):832-835.

[117]Roberts, S.K., Cooksley, G., Dore, G.J., Robson, R., Shaw, D., Berns, H., Hill, G., Klumpp, K., Najera, I., Washington, C., 2008. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology, 48(2):398-406.

[118]Salmon-Ceron, D., Lewden, C., Morlat, P., Bevilacqua, S., Jougla, E., Bonnet, F., Heripret, L., Costagliola, D., May, T., Chene, G., 2005. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J. Hepatol., 42(6):799-805.

[119]Sarrazin, C., Rouzier, R., Wagner, F., Forestier, N., Larrey, D., Gupta, S.K., Hussain, M., Shah, A., Cutler, D., Zhang, J., et al., 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon α-2b for genotype 1 nonresponders. Gastroenterology, 132(4):1270-1278.

[120]Schiff, E., Poordad, F.F., Jacobson, I.M., Flamm, S.L., Bacon, B.R., Lawitz, E.J., Gordon, S.R., McHutchison, J.G., Ghalib, R., Poynard, T., et al., 2008. Role of interferon response during RE-Treatment of null responders with boceprevir combination therapy: results of phase II trial. Gastroenterology, 134(4):A755.

[121]Schmitz, U., Tan, S.L., 2008. NS5A—from obscurity to new target for HCV therapy. Recent Pat. Anti-Infect. Drug Discov., 3(2):77-92.

[122]Seth, R.B., Sun, L., Chen, Z.J., 2006. Antiviral innate immunity pathways. Cell Res., 16(2):141-147.

[123]Shepard, C.W., Finelli, L., Alter, M.J., 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis., 5(9):558-567.

[124]Shi, S.T., Herlihy, K.J., Graham, J.P., Nonomiya, J., Rahavendran, S.V., Skor, H., Irvine, R., Binford, S., Tatlock, J., Li, H., et al., 2009. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother., 53(6):2544-2552.

[125]Shih, I.H., Vliegen, I., Peng, B., Yang, H., Paeshuyse, J., Purstinger, G., Fenaux, M., Mabery, E., Bahador, G., Lehman, L.S., et al., 2007. Mechanistic characterization of GS-9190, a novel non-nucleoside inhibitor of HCV NS5B polymerase with potent antiviral activity and a unique mechanism of action. Hepatology, 46(4):859A.

[126]Simmonds, P., 2004. Genetic diversity and evolution of hepatitis C virus—15 years on. J. Gen. Virol., 85(11):3173-3188.

[127]Stauber, K., Marlor, C.W., Mushtaq, G., Gadhachanda, V., Pais, G., Hashimoto, A., Phadke, A., Huang, M., Deshpande, M., 2010. Characterization of the hepatoselective distribution of ACH-1625, a potent, clinical stage HCV NS3 protease inhibitor. J. Hepatol., 52(S1):S299.

[128]Susan, H., 2010. Gilead’s Investigational Hepatitis C Compounds GS 9190 and GS 9256 in Combination with Standard of Care Therapies Achieve Substantial Viral Suppression in Phase II Study. Available from http://www.gilead.com/pr_1489408 [Accessed on Nov. 20, 2011]

[129]Tang, H., Grise, H., 2009. Cellular and molecular biology of HCV infection and hepatitis. Clin. Sci., 117(2):49-65.

[130]Tellinghuisen, T.L., Foss, K.L., 2008. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog., 4(3):e1000032.

[131]Thompson, P.A., Patel, R., Showalter, R.E., Li, C., Applemon, J.R., Steffy, K., 2008. In vitro studies demonstrate that combinations of antiviral agents that include HCV polymerase inhibitor ANA598 have the potential to overcome viral resistance. Hepatology, 48(4):1164A.

[132]Thompson, P., Patel, R., Steffy, K., Appleman, J., 2009. Preclinical studies of ANA598 combined with other anti-HCV agents demonstrate potential of combination treatment. J. Hepatol., 50(S1):S37.

[133]Thompson, P., Showalter, R., Patel, R., Appleman, J., 2010a. In vitro combination of ANA598 with other anti-HCV agents can eliminate the emergence of resistant colonies. Antivir. Res., 86(1):A48.

[134]Thompson, P.A., Showalter, R.E., Patel, R.A., Appleman, J.R., 2010b. Enhanced in vitro antiviral activity of ANA598 in combination with other anti-HCV Agents support combination treatment. J. Hepatol., 52(S1):S262.

[135]Tong, X., Arasappan, A., Bennett, F., Chase, R., Feld, B., Guo, Z., Hart, A., Madison, V., Malcolm, B., Pichardo, J., et al., 2010. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. Antimicrob. Agents Chemother., 54(6):2365-2370.

[136]Troke, P., Lewis, M., Simpson, P., van der Ryst, E., Hammond, J., Craig, C., Perros, M., Westby, M., 2009. Genotypic characterisation of HCV NS5B following 8-day monotherapy with the polymerase inhibitor PF-00868554 in HCV-infected subjects. J. Hepatol., 50(S1):S351.

[137]Vliegen, I., Paeshuyse, J., Marbery, E., Peng, B., Shih, H., Lehman, L.S., Dutartre, H., Selisko, B., Canard, B., Bondy, S., et al., 2007. GS-9190, a novel substituted imidazopyridine analogue, is a potent inhibitor of hepatitis C virus replication in vitro and remains active against known drug resistant mutants. Hepatology, 46(4):855A.

[138]Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Krausslich, H.G., Mizokami, M., et al., 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med., 11(7):791-796.

[139]Walker, M.P., Hong, Z., 2002. HCV RNA-dependent RNA polymerase as a target for antiviral development. Cur. Opin. Pharmacol., 2(5):534-540.

[140]Wang, C., Sarnow, P., Siddiqui, A., 1993. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. J. Virol., 67(6):3338-3344.

[141]Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M., Shimotohno, K., 2003. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology, 38(5):1282-1288.

[142]Weisberg, I.S., Jacobson, I.M., 2009. Telaprevir: hope on the horizon, getting closer. Clin. Liver Dis., 13(3):441-452.

[143]White, P.W., Llinas-Brunet, M., Amad, M., Bethell, R.C., Bolger, G., Cordingley, M.G., Duan, J.M., Garneau, M., Lagace, L., Thibeault, D., et al., 2010a. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob. Agents Chemother., 54(11):4611-4618.

[144]White, P.W., Llinas-Brunet, M., Amad, M., Bolger, G., Cordingley, M.G., Duan, J., Garneau, M., Lagace, L., Thibeault, D., Kukolj, G., 2010b. Preclinical characterization of non-covalent HCV NS3/4A protease inhibitor BI 201335. J. Hepatol., 52(S1):S302.

[145]Wong, D.A., Tong, L.K., Lim, W., 1998. High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong. Eur. J. Epidemiol., 14(5):421-426.

[146]Yang, C., Wang, Y., Wieman, L., Eisenberg, E., Lee, M., Murray, B., Tong, L., Ray, A., Bondy, S., Tse, W., et al., 2007. Preclinical pharmacokinetic characterization of GS-9190, a novel non-nucleoside HCV NS5B polymerase inhibitor. Hepatology, 46(4):860A-861A.

[147]Yi, M., Lemon, S.M., 2003. 3′-nontranslated RNA signals required for replication of hepatitis C virus RNA. J. Virol., 77(6):3557-3568.

[148]Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D.R., Wielandm, S.F., Uprichard, S.L., Wakita, T., Chisari, F.V., 2005. Robust hepatitis C virus infection in vitro. PNAS, 102(26):9294-9299.

[149]Zhou, X.J., Pietropaolo, K., Sullivan-Bolyai, J., Kuca, B., Liu, W., Xu, L., Belanger, B., Khan, S., Mayers, D., 2009. IDX184, a liver-targeted nucleotide HCV polymerase inhibitor: results of a first-in-man safety and pharmacokinetic study. J. Hepatol., 50(S1):S351.